HPV vaccine shown to reduce genital wart rate in young women
The HPV vaccine offers protection against the various types of HPV that cause 90 percent of genital warts and different types of cancer-causing HPV strains.
Data found by researchers from the University of New South Wales and Melbourne Sexual Health Centre showed that ever since the vaccine was introduced as a national sponsored program, diagnoses of genital warts decreased by 59 percent in women ages 12-26 and by 39 percent in heterosexual men. There was also a decrease in the number of cervical abnormalities in women under the age of 18.
There were no significant changes in the trends seen in women who were 30 or over.
In an editorial, Clinical Director Simon Barton and Sexual Health and HIV consultant Colm O'Mahony said the news is worth celebrating and shows an extraordinary success. They also said the HPV vaccine will have a major impact on the cost of sexual healthcare and that they hope the trend will continued and be mirrored in the U.K., which is not adopting a similar system to Australia's.
Barton and Colm said these results show that a time may come in the future where genital warts and most genital cancers could be eliminated.